Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Benjamin H Lowentritt"'
Autor:
Benjamin H. Lowentritt, Carmine Rossi, Erik Muser, Frederic Kinkead, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Shawn Du
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 11, Iss 2 (2024)
**Background:** The use of androgen receptor signaling inhibitors, including apalutamide, in combination with androgen deprivation therapy is recommended for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic
Externí odkaz:
https://doaj.org/article/89ca6cb7e129487691a432f47155435f
Autor:
Benjamin H. Lowentritt, MD, Ashesh B. Jani, MD, Brian T. Helfand, MD, Edward M. Uchio, MD, Michael A. Morris, MD, Jeff M. Michalski, MD, Albert Chau, MSc, Phillip Davis, MD, Brian F. Chapin, MD, David M. Schuster, MD
Publikováno v:
Advances in Radiation Oncology, Vol 9, Iss 8, Pp 101532- (2024)
Purpose: 18F-Flotufolastat (18F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated 18F-flotufolasta
Externí odkaz:
https://doaj.org/article/0a78797c6fb84535b5a1b6769c51c1c9
Publikováno v:
Prostate Cancer, Vol 2020 (2020)
The positron emission tomography (PET) tracer 18F-fluciclovine has seen increasing use to localize disease in men with biochemical recurrence of prostate cancer, i.e., elevated prostate-specific antigen (PSA) levels post-treatment. 18F-Fluciclovine P
Externí odkaz:
https://doaj.org/article/0148ea720fad41cf852499c2ae860ae8
Autor:
Benjamin H, Lowentritt
Publikováno v:
Clinical advances in hematologyoncology : HO. 20(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c491d3fa80758bd86056b496338cae0e
https://pubmed.ncbi.nlm.nih.gov/35343943
https://pubmed.ncbi.nlm.nih.gov/35343943
Autor:
Alicia K. Morgans, Jeffrey M. Spier, Michael S. Cookson, Jason Hafron, E. David Crawford, Gordon A. Brown, Jonathan Henderson, Emmanuel S. Antonarakis, Neal D. Shore, Daniel Saltzstein, Raoul S. Concepcion, David M. Albala, Benjamin H Lowentritt, Richard G. Harris
Publikováno v:
The Prostate
Background For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef0d1044ced67865ffc9f16a920762ac
https://doi.org/10.1002/pros.23967
https://doi.org/10.1002/pros.23967
Publikováno v:
Prostate Cancer, Vol 2020 (2020)
The positron emission tomography (PET) tracer 18F-fluciclovine has seen increasing use to localize disease in men with biochemical recurrence of prostate cancer, i.e., elevated prostate-specific antigen (PSA) levels post-treatment. 18F-Fluciclovine P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cea8e506e7e54a80c0a40b8ebb36f792
https://doi.org/10.1155/2020/1929565
https://doi.org/10.1155/2020/1929565
Autor:
Benjamin H Lowentritt, Shawn Du, Carmine Rossi, Frederic Kinkead, Dexter Waters, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Erik Muser
Publikováno v:
Journal of Clinical Oncology. 41:69-69
69 Background: For patients with nmCRPC, APA with androgen deprivation therapy is an important therapeutic option with demonstrated efficacy in improving metastasis-free survival (MFS), and other clinical outcomes. However, there is limited real-worl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c2896cbcd6ad33d4320a33fd56124bd
https://doi.org/10.1200/jco.2023.41.6_suppl.69
https://doi.org/10.1200/jco.2023.41.6_suppl.69
Autor:
Benjamin H Lowentritt, Carmine Rossi, Shawn Du, Erik Muser, Frederic Kinkead, Dexter Waters, Patrick Lefebvre, Dominic Pilon, Neeraj Agarwal
Publikováno v:
Journal of Clinical Oncology. 41:65-65
65 Background: CR is an important clinical indicator of disease progression and worsening overall survival among pts with mCSPC. This study describes real-world time-to-CR progression in an oncology setting among pts with mCSPC who initiated APA, ENZ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38c1ea95f6d8a9d614432191431e5b18
https://doi.org/10.1200/jco.2023.41.6_suppl.65
https://doi.org/10.1200/jco.2023.41.6_suppl.65
Autor:
Daniel Eidelberg Spratt, Rana R. McKay, Tanya B. Dorff, Benjamin H Lowentritt, Mark Fallick, Sarah Hanson, Ashley Ross
Publikováno v:
Journal of Clinical Oncology. 41:TPS398-TPS398
TPS398 Background: Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) receptor agonists or antagonists are the foundation of advanced prostate cancer (aPC) treatment. Relugolix is an oral non-peptide GnRH receptor antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52701d593f69a736e738969290b7952b
https://doi.org/10.1200/jco.2023.41.6_suppl.tps398
https://doi.org/10.1200/jco.2023.41.6_suppl.tps398
Autor:
Dominic Pilon, Guillaume Germain, Patrick Lefebvre, Lorie Ellis, Gordon D. Brown, Benjamin H. Lowentritt, Neal D. Shore, Paul Sieber, Kenneth Kernen, Carmine Del Rossi
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Real-world evidence on apalutamide (APA), recently approved to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC), is limited in the United ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b8e726b3eb3bd486bd910e8cf0102da
https://doi.org/10.1097/ju.0000000000001969.08
https://doi.org/10.1097/ju.0000000000001969.08